Aphria becomes one of the first suppliers of
adult-use cannabis to La Belle Province
LEAMINGTON, ON, Feb. 14, 2018 /CNW/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APH and
US OTC: APHQF) today announced that it has signed a Letter of
Intent with the Société des alcools du Québec ("SAQ") to
guarantee a supply of high-quality, safe and clean cannabis
products for sale in the Quebec
adult-use market through their retail outlets and e-commerce
platform.
"We're thrilled to partner with the SAQ to supply the
Quebec adult-use market with a
variety of high-quality, safe and pure cannabis products," said
Vic Neufeld, Chief Executive Officer
of Aphria. Aphria is uniquely positioned to meet the anticipated
demand in Canada's second-largest
market and we are pleased to be working closely with the SAQ and
its management team as one of the first suppliers to the
province."
Under the terms of the agreement, the Company will supply the
Quebec market with up to 12,000 kg
of branded cannabis products in the first year of the agreement,
including cannabis oils and other derivative products and several
strains of high-quality Ontario-
and B.C.-grown dried cannabis flower.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight,
allowing for the most natural growing conditions available. Aphria
is committed to providing pharma-grade medical cannabis, superior
patient care while balancing patient economics and returns to
shareholders.
For more information, visit: www.aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual volumes
under the agreement, expectations for future growing capacity and
costs, the completion of any capital project or expansions, and
expectations with respect to future production costs.
Forward-looking statements necessarily involve known and unknown
risks, including, without limitation, risks associated with general
economic conditions; adverse industry events; marketing costs; loss
of markets; future legislative and regulatory developments
involving medical marijuana; inability to access sufficient capital
from internal and external sources, and/or inability to access
sufficient capital on favourable terms; the medical marijuana
industry in Canada generally,
income tax and regulatory matters; the ability of Aphria to
implement its business strategies; competition; crop failure;
currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.